Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Trade Show, Webcast

Enanta Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on June 18, 2020 at 10:20 a.m. ET.

A live webcast will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.

About Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection, under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.


These press releases may also interest you

at 10:12
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

at 10:02
Completion of Largest Capacity GMP Run Marks New Standard in Biologics Manufacturing
Boston Institute of Biotechnology, LLC (BIB) in collaboration with BIBo-Biopharma, proudly announces the successful completion of a groundbreaking 30,000L fermentation run, marking a significant milestone in biotechnology history....

at 10:00
Missing Indigenous children: a third review since the Act came into force
Minister Responsible for Relations with the First Nations and the Inuit Ian Lafrenière today submitted in the National Assembly the third annual report on the administration of the Act to authorize the communication of personal information to the...

at 10:00
Cobb Outpatient Detox Opens New Outpatient Drug and Alcohol Detox Facility in Marietta, GA
Cobb Outpatient Detox has opened a new facility in Marietta, GA, providing outpatient drug and alcohol detox services. The center aims to assist individuals in overcoming addiction while balancing their work and family commitments. Located near major...

at 10:00
PER PERSON HEALTH CARE SPENDING EXCEEDED $6,700 IN 2022
A new report from the Health Care Cost Institute (HCCI) shows that, even with fluctuations in 2020 and 2021, per person health care spending grew from 2018 to 2022. Over the five years, average prices increased by 14% and utilization went up by about...

at 10:00
BioInnovation Institute & Science announce the launch of the Translational Medicine Prize for Innovations in Women´s Health and Gender Medicine
BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces the launch of the BII & Science Translational Medicine Prize for Innovations in Women´s Health and...

More news about Health...


News published on and distributed by: